PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26381275-1	2015	PURPOSE: To investigate the potential effects of strong CYP3A inhibitor ketoconazole and strong CYP3A inducer rifampin on the pharmacokinetics of crizotinib in human.	Crizotinib	146-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61	
33222380-0	2021	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.	Crizotinib	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-155	
33222380-3	2021	We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure.	Crizotinib	96-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33	
33222380-3	2021	We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure.	Crizotinib	96-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-85	
31127319-2	2019	Crizotinib is a selective tyrosine kinase inhibitor of ALK, ROS1, and MET and a substrate of CYP3A.	Crizotinib	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98	
31127319-5	2019	Frequency and reasons for use of concomitant CYP3A inducers, including dexamethasone, with crizotinib were characterized.	Crizotinib	91-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-50	
26381275-1	2015	PURPOSE: To investigate the potential effects of strong CYP3A inhibitor ketoconazole and strong CYP3A inducer rifampin on the pharmacokinetics of crizotinib in human.	Crizotinib	146-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-101	
26381275-5	2015	RESULTS: Co-administration of a single 150-mg oral dose of crizotinib with the strong CYP3A inhibitor ketoconazole resulted in an area under the plasma-concentration curve extrapolated to infinity (AUC0-inf) 3.2-fold that for crizotinib alone.	Crizotinib	59-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91	
26381275-5	2015	RESULTS: Co-administration of a single 150-mg oral dose of crizotinib with the strong CYP3A inhibitor ketoconazole resulted in an area under the plasma-concentration curve extrapolated to infinity (AUC0-inf) 3.2-fold that for crizotinib alone.	Crizotinib	226-236	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91	
26381275-6	2015	Co-administration of a single 250-mg crizotinib dose with the strong CYP3A inducer rifampin caused an 82 % decrease in crizotinib AUC0-inf.	Crizotinib	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74	
26381275-6	2015	Co-administration of a single 250-mg crizotinib dose with the strong CYP3A inducer rifampin caused an 82 % decrease in crizotinib AUC0-inf.	Crizotinib	119-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74	
26381275-8	2015	CONCLUSIONS: These findings suggest that CYP3A plays an important role in the metabolism of both crizotinib and PF-06260182, with the extent of this role being greater for PF-06260182.	Crizotinib	97-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-46	
23686600-4	2013	Crizotinib is metabolized and excreted after O-dealkylation by cytochrome P-450 (CYP) isoenzyme 3A4/5; as crizotinib is also an inhibitor of CYP3A4/5, its use entails a high potential for drug interactions, including confirmed interactions with ketoconazole and rifampin that can alter crizotinib pharmacokinetics.	Crizotinib	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147	
26180127-0	2015	Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.	Crizotinib	42-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65	
26180127-1	2015	An orally available multiple tyrosine kinase inhibitor, crizotinib (Xalkori), is a CYP3A substrate, moderate time-dependent inhibitor, and weak inducer.	Crizotinib	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88	
26180127-8	2015	Overall, we believe that the crizotinib PBPK model developed, refined, and verified in the present study would adequately predict crizotinib oral exposures in other clinical studies, such as DDIs with weak/moderate CYP3A inhibitors/inducers and drug-disease interactions in patients with hepatic or renal impairment.	Crizotinib	29-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-220	
23686600-4	2013	Crizotinib is metabolized and excreted after O-dealkylation by cytochrome P-450 (CYP) isoenzyme 3A4/5; as crizotinib is also an inhibitor of CYP3A4/5, its use entails a high potential for drug interactions, including confirmed interactions with ketoconazole and rifampin that can alter crizotinib pharmacokinetics.	Crizotinib	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147	
23129213-5	2013	Crizotinib E(max) and EC(50) for CYP3A4 induction (measured as mRNA expression) were estimated as 6.4- to 29-fold and 0.47 to 3.1 microM, respectively.	Crizotinib	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39	
23129213-0	2013	Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.	Crizotinib	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-111